トータルネオアジュバントセラピー
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Conroy T, Castan F, Etienne PL, et al. Ann Oncol. 2024 O…
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.Lin ZY, Zhang P, Chi P, et al. Ann Oncol. 2024 Oct;35(10)…
Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial.Gani C, Fokas E, Polat B, et al. Lancet Gastroenterol Hepatol. 2025 Jun;10(6):562…
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.Verheij FS, Omer DM, Williams H, et al. J Clin Oncol. 2024 Feb 10;42(5):500-506. DOI:…
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials.Fokas E, Williams H, Diefenhardt M…
Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).Jin J, Tang Y, Hu C, et al. J Clin Oncol. 2022 May 20;40(15):1681-1692. do…
Post-hoc analysis of clinicopathological factors affecting lateral lymph node metastasis based on STELLAR study for rectal cancer. Chen LN, Jiang J, Jiang LM, et al. Radiother Oncol. 2024 Nov;200:110512. doi: 10.1016/j.radonc.2024.110512. …
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study.Lin Z, Zhang P, Cai M, et al. BMC Med. 2025 May 9;23(1):273. DOI: 10.1186/s12916-025-0…
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. Rahma OE, Yothers G, Hong TS, et al. JAMA Oncol. 2021 Aug 1;7(8):1225-1230. DOI: 10.100…
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study. Shamseddine A, Turfa R, Chehade L, et al. Eur J Cancer. 2025 Jun 3;222:115428. DOI: 10.1016/j…
Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer. Haraguchi E, Akiyoshi T, Noguchi T, et al. Int J Cancer. 2025 Jul 14. DOI: 10.1002/ijc.70040 Epub ahead of print. P…
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Conroy T, Castan F, Etienne PL, et al. Ann Oncol. 2024 O…
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.Conroy T, Bosset JF, Etienne PL, et a…
Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-0…
